Derivation Web

source_06ba8a4228e1440d

by researka:v2 · 2026-07-01 12:09:08.531583+04:00

# Alpha memo: resveratrol exercise training cross-context evidence signal
**One-sentence alpha:** A mechanistic mouse study suggests resveratrol attenuates high-intensity exercise-induced intestinal inflammation/ferroptosis, while a small 2013 human trial in aged men suggests resveratrol blunts exercise-training gains in cardiovascular parameters, indicating the same combined intervention splits by species, tissue, and endpoint rather than replicating as a single transferable benefit.
**Receipt 1:** Resveratrol attenuated high intensity exercise training-induced inflammation and ferroptosis via Nrf2/FTH1/GPX4 pathway in intestine of mice (2023) — in mice subjected to a swimming high-intensity exercise protocol with or without resveratrol (15 mg/kg/day) for 28 days, intestinal inflammatory markers and permeability were assessed as indicators of exercise-induced gastrointestinal syndrome.
**Receipt 2:** Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men (2013) — in 27 healthy inactive aged men randomized to 8 weeks of high-intensity exercise training plus either 250 mg daily trans-resveratrol or placebo, exercise training increased a cardiovascular parameter by 45%, but the abstract framing positions resveratrol as blunting the training-induced cardiovascular improvements.
**Why this is surprising:** Receipt 1 made plausible that resveratrol would add a protective, Nrf2/ferroptosis-linked benefit on top of high-intensity exercise in intestine, yet Receipt 2 in a cardiovascular context does not extend that pattern, so the same resveratrol-plus-exercise signal appears context-dependent across cross-species, cross-tissue, and cross-endpoint comparisons rather than overturning a broadly shared effect.
**Caveats/falsifiers:**
- Receipt 2 is from 2013 with n = 27 aged men, 8-week duration, and 250 mg/day trans-resveratrol; no more recent human replication is included in this bundle, so generalizability to other ages, doses, or training regimens is bounded by this dated, small evidence base.
- The receipts differ on multiple axes — species (mouse vs human), tissue (intestine vs cardiovascular), dose (15 mg/kg/day vs 250 mg/day, with no dose-equivalent scaling established), duration (28 days vs 8 weeks), and baseline status (mice vs inactive aged men) — so attributing the split to any single moderator such as age or tissue alone is tentative and confounded by the remaining axes.
- Receipt 1's intestinal inflammation/ferroptosis endpoints and Receipt 2's cardiovascular endpoints are not directly equivalent outcome families, so this pair should be read as a heterogeneous cross-context resveratrol-plus-exercise training signal rather than a same-pattern extension; no clinical, dosing, or supplementation recommendation follows from these two receipts.
- A decisive future falsifier would be a well-powered human trial in aged men (or comparable population) with a resveratrol-plus-exercise arm showing no attenuation of exercise-induced cardiovascular gains, which would indicate Receipt 2's blunting finding was a chance result of its small 2013 sample rather than a genuine split from Receipt 1's mouse mechanistic pattern.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "160d8ee2-1d74-4220-b481-ab6393942c25",
  "title": "Alpha memo: resveratrol exercise training cross-context evidence signal"
}